C20-OtBu-γ-Glu(OtBu)-AEEA-AEEA-OH | CAS 1188328-37-1

C20-OtBu-γ-Glu(OtBu)-AEEA-AEEA-OH | CAS 1188328-37-1

C20-OtBu-γ-Glu(OtBu)-AEEA-AEEA-OH, CAS 1188328-37-1, is a protected C20 lipid side-chain building block used in peptide lipidation and Tirzepatide-related peptide synthesis.

The molecule combines a protected C20 lipid moiety with a γ-glutamic acid unit and an AEEA-AEEA spacer. This modular architecture makes it suitable for peptide development routes that require installation of a long-chain lipid side chain while maintaining controlled spacing between the peptide backbone and hydrophobic lipid component.

In Tirzepatide-related synthetic routes, CAS 1188328-37-1 is commonly positioned as a protected non-activated side-chain fragment that can be further converted or coupled into more advanced peptide building blocks.

Basic Information

Product Features

Protected C20 Lipid Side-Chain Architecture

The product contains a protected C20 lipid segment designed for incorporation into lipid-modified peptide structures.

Temporary tert-butyl protection helps control reactive carboxyl functionalities during intermediate preparation and multistep peptide synthesis, allowing the side-chain fragment to be handled before final deprotection.

γ-Glu and AEEA-AEEA Spacer Design

The side-chain structure combines γ-Glu with two AEEA units.

AEEA-based spacers provide a flexible and relatively hydrophilic connection between peptide-related structures and lipid components. This type of spacer architecture is useful in peptide lipidation strategies where separation between the peptide backbone and long-chain lipid moiety is required.

For customers working with linker-related building blocks, Juntai also supplies AEEA-AEEA CAS 1143516-05-5, which serves as a useful upstream linker component in peptide modification chemistry. 

Suitable for Tirzepatide-Related Side-Chain Assembly

CAS 1188328-37-1 is commercially recognized as a Tirzepatide-related side-chain intermediate and is used in the preparation of more advanced lipidated peptide building blocks.

It should be understood as a side-chain intermediate rather than as Tirzepatide itself or as a finished peptide API.

This distinction is important for product identification, route design, procurement, and analytical control.

Non-Activated Side-Chain Intermediate

The molecule is supplied as a protected side-chain fragment with a terminal carboxyl functionality available for further derivatization or coupling.

Depending on the selected synthesis strategy, downstream steps may involve activation of the carboxyl group or incorporation into a protected lysine building block before introduction into a growing peptide chain.

Research and Process Applications

Tirzepatide-Related Peptide Synthesis

One of the most important applications of C20-OtBu-γ-Glu(OtBu)-AEEA-AEEA-OH is in Tirzepatide-related side-chain chemistry.

Tirzepatide contains a lipid-modified peptide architecture involving a C20 fatty-acid-derived side chain connected through linker units. CAS 1188328-37-1 represents an important protected fragment used in the construction of this type of side-chain system.

Juntai also supplies Tirzepatide CAS 2023788-19-2 for peptide research and analytical applications. The Tirzepatide product page identifies the molecule as a 39-amino-acid lipid-modified peptide containing a C20 fatty-acid side chain. 

Peptide Lipidation

Peptide lipidation involves attachment of a hydrophobic lipid component to a peptide through a defined linker architecture.

C20-OtBu-γ-Glu(OtBu)-AEEA-AEEA-OH can be used as a peptide lipidation building block during development of lipid-modified peptide structures.

The combination of a C20 lipid component, γ-Glu, and AEEA-AEEA spacer provides a modular framework for side-chain assembly and subsequent incorporation into peptide intermediates.

Side-Chain Coupling Route Development

For process-development teams, the side-chain fragment can be evaluated in different synthetic strategies, including:

• Direct side-chain activation
• Coupling to modified lysine derivatives
• Preparation of preassembled lipidated amino acid building blocks
• Subsequent incorporation into peptide sequences
• Route optimization for repeat or larger-scale synthesis

The most appropriate route depends on the target peptide structure, coupling chemistry, impurity profile, and production scale.

Relationship to CAS 2915356-76-0

CAS 1188328-37-1 and CAS 2915356-76-0 are related but are not the same intermediate.

In CAS 2915356-76-0, the C20-Glu-AEEA-AEEA side chain is already attached to a protected lysine residue. This provides a more advanced building block for peptide synthesis.

You can view the related product here: Fmoc-L-Lys[C20-OtBu-γ-Glu(OtBu)-AEEA-AEEA]-OH CAS 2915356-76-0. Your current site already identifies this product as a modified amino acid building block used in Tirzepatide synthesis. 

Custom Synthesis Support

Shandong Juntai Pharmaceutical supports the supply and custom development of peptide side-chain intermediates, AEEA-based linkers, lipidated peptide building blocks, protected amino acid derivatives, and peptide intermediates for R&D and process-development projects.

Project requirements can be discussed according to:

• Target side-chain structure
• Purity and impurity specifications
• HPLC and MS requirements
• Activated or non-activated intermediate form
• Batch quantity
• Scale-up requirements
• Repeat supply planning
• Customized packaging

For customers sourcing a Tirzepatide side-chain intermediate supplier, C20 peptide building blocks, or related AEEA-based intermediates, project specifications can be evaluated before quotation to ensure that the supplied material matches the intended synthesis route.

Related building blocks available from Juntai include Fmoc-AEEA CAS 166108-71-0 and AEEA-AEEA CAS 1143516-05-5. 

FAQ

What information should I provide when requesting a quotation for CAS 1188328-37-1?

Please provide the required quantity, target purity or specification, destination, packaging requirements, and any special analytical requirements. For process-development or repeat-supply projects, projected demand is also helpful for supply planning.

Can you provide COA, HPLC and MS data for each batch?

Available batch documentation can include a Certificate of Analysis and relevant analytical results according to the agreed specification. HPLC, MS, moisture, residual solvents, or other project-specific analytical requirements should be confirmed before order placement.

Can purity or impurity specifications be customized?

Yes. Project-specific purity, impurity limits, analytical methods, and other control parameters can be evaluated according to technical feasibility. This is especially relevant for side-chain intermediates used in peptide process development, where impurity profiles may influence downstream coupling and purification.

What is the difference between CAS 1188328-37-1 and CAS 2915356-76-0?

CAS 1188328-37-1 is a protected C20-Glu-AEEA-AEEA side-chain fragment, while CAS 2915356-76-0 is a more advanced Fmoc-protected lysine building block in which the C20-Glu-AEEA-AEEA side chain has already been installed on lysine.

The appropriate intermediate therefore depends on the customer's peptide synthesis route and the stage at which the lipid side chain will be introduced.

Can Juntai supply related Tirzepatide side-chain intermediates and AEEA-based building blocks?

Yes. Juntai can evaluate supply or custom synthesis requirements for AEEA-based linkers, protected C20 side-chain intermediates, modified lysine building blocks, and related peptide intermediates. Providing the target structure, required quantity, target purity, and analytical requirements will help accelerate project assessment.

For research, process development, and industrial applications only. Product specifications and supply arrangements should be confirmed according to individual project requirements.